Your browser doesn't support javascript.
loading
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson, Andrew D J; Federico, Sara; Gatz, Susanne A; Ortiz, Michael; Lesa, Giovanni; Scobie, Nicole; Gounaris, Ioannis; Weiner, Susan L; Weigel, Brenda; Unger, T J; Stewart, Elizabeth; Smith, Malcolm; Slotkin, Emily K; Reaman, Gregory; Pappo, Alberto; Nysom, Karsten; Norga, Koen; McDonough, Joe; Marshall, Lynley V; Ludwinski, Donna; Ligas, Franca; Karres, Dominik; Kool, Marcel; Horner, Thierry J; Henssen, Anton; Heenen, Delphine; Hawkins, Douglas S; Gore, Lia; Bender, Julia Glade; Galluzzo, Sara; Fox, Elizabeth; de Rojas, Teresa; Davies, Barry R; Chakrabarti, Jayeta; Carmichael, Juliet; Bradford, Diana; Blanc, Patricia; Bernardi, Ronald; Benchetrit, Sylvie; Akindele, Korede; Vassal, Gilles.
Afiliação
  • Pearson ADJ; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium. Electronic address: andy1pearson@btinternet.com.
  • Federico S; St Jude Children's Research Hospital, Memphis, TN, USA.
  • Gatz SA; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Ortiz M; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands.
  • Scobie N; Zoe4Life, Sullens, Switzerland.
  • Gounaris I; Merck Serono Ltd (an affiliate of Merck KGaA, Darmstadt, Germany), Feltham, UK.
  • Weiner SL; Children's Cancer Cause, Washington, DC, USA.
  • Weigel B; University of Minnesota, Minneapolis, MN, USA.
  • Unger TJ; Repare Therapeutics, Cambridge, MA, USA.
  • Stewart E; St Jude Children's Research Hospital, Memphis, TN, USA.
  • Smith M; National Cancer Institute, Bethesda, MD, USA.
  • Slotkin EK; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Reaman G; US Food and Drug Administration, Silver Springs, MD, USA.
  • Pappo A; St Jude Children's Research Hospital, Memphis, TN, USA.
  • Nysom K; Righospitalet, Copenhagen, Denmark.
  • Norga K; Antwerp University Hospital, Antwerp, Belgium; Paediatric Committee of the European Medicines Agency (EMA), Amsterdam, the Netherlands; Federal Agency for Medicines and Health Products, Brussels, Belgium.
  • McDonough J; The Andrew McDonough B+ Foundation, Wilmington, DE, USA.
  • Marshall LV; The Royal Marsden NHS Foundation Hospital, The Institute of Cancer Research, Sutton, Surrey, UK.
  • Ludwinski D; Solving Kids' Cancer, New York, NY, USA.
  • Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands.
  • Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, the Netherlands.
  • Kool M; Hopp Children's Cancer Center, Heidelberg, Germany.
  • Horner TJ; GSK, Collegeville, PA, USA.
  • Henssen A; Charité Berlin, Berlin, Germany.
  • Heenen D; KickCancer, Brussels, Belgium.
  • Hawkins DS; Seattle Children's Hospital, Seattle, WA, USA; Children's Oncology Group, Seattle, WA, USA.
  • Gore L; Children's Hospital Colorado, Aurora, CO, USA; University of Colorado School of Medicine, Aurora, CO, USA.
  • Bender JG; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Galluzzo S; Italian Medicine Agency (AIFA), Rome, Italy.
  • Fox E; St Jude Children's Research Hospital, Memphis, TN, USA.
  • de Rojas T; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium.
  • Davies BR; AstraZeneca, Cambridge, UK.
  • Chakrabarti J; Pfizer, Tadworth, UK.
  • Carmichael J; The Royal Marsden NHS Foundation Hospital, The Institute of Cancer Research, Sutton, Surrey, UK.
  • Bradford D; US Food and Drug Administration, Silver Springs, MD, USA.
  • Blanc P; Imagine for Margo, Paris, France.
  • Bernardi R; Genentech, a Member of the Roche Group, South San Francisco, CA, USA.
  • Benchetrit S; National Agency for the Safety of Medicine and Health Products, Paris, France.
  • Akindele K; The Dorcas Foundation, Lagos, Nigeria.
  • Vassal G; ACCELERATE, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30 BE-1200 Brussels, Belgium; Gustave Roussy Cancer Centre, Paris, France.
Eur J Cancer ; 190: 112950, 2023 09.
Article em En | MEDLINE | ID: mdl-37441939
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuroblastoma / Antineoplásicos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuroblastoma / Antineoplásicos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article